10x Genomics (NASDAQ:TXG) Cut to “Hold” at Wall Street Zen

10x Genomics (NASDAQ:TXG) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

TXG has been the subject of several other reports. Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a research report on Monday, August 11th. Barclays reaffirmed an “overweight” rating and issued a $15.00 target price (up from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a “hold” rating in a research report on Friday, August 8th. UBS Group raised their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research report on Saturday, August 30th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.65.

10x Genomics Stock Down 3.2%

Shares of 10x Genomics stock opened at $12.64 on Friday. The firm has a market cap of $1.57 billion, a PE ratio of -18.06 and a beta of 2.00. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $24.38. The company’s fifty day simple moving average is $13.21 and its two-hundred day simple moving average is $10.81.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. During the same period last year, the company posted ($0.32) EPS. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Activity at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,149 shares of company stock valued at $539,865 in the last three months. Company insiders own 9.39% of the company’s stock.

Institutional Trading of 10x Genomics

A number of institutional investors and hedge funds have recently bought and sold shares of TXG. Allworth Financial LP increased its stake in 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after purchasing an additional 1,364 shares in the last quarter. GAMMA Investing LLC increased its stake in 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after purchasing an additional 1,614 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in 10x Genomics during the 4th quarter valued at about $32,000. Signaturefd LLC increased its stake in 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock valued at $37,000 after purchasing an additional 2,409 shares in the last quarter. Finally, Whittier Trust Co. bought a new stake in 10x Genomics during the 1st quarter valued at about $41,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.